LI Shidong, LV Rui, JIN Xin. Efficacy and safety of paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule in the treatment of patients with advanced gastric carcinoma[J]. Journal of Clinical Medicine in Practice, 2014, (13): 113-115. DOI: 10.7619/jcmp.201413038
Citation: LI Shidong, LV Rui, JIN Xin. Efficacy and safety of paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule in the treatment of patients with advanced gastric carcinoma[J]. Journal of Clinical Medicine in Practice, 2014, (13): 113-115. DOI: 10.7619/jcmp.201413038

Efficacy and safety of paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule in the treatment of patients with advanced gastric carcinoma

More Information
  • Published Date: September 10, 2014
  • Objective To explore the short-term efficacy and toxic and adverse responses of paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule in the treatment of pa-tients with advanced gastric carcinoma.Methods Paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule were given to 36 elderly patients diagnosed with advanced gastric carci-noma so as to evaluate the clinical efficacy and toxic and adverse responses.Results All patients were available to evaluate the clinical efficacy and toxic and adverse responses,with response rate, disease control rate and medium survival time being 44.4%,80.6% and 9.2 months.The main ad-verse responses were myelosuppression and gastrointestinal responses in degree Ⅰ~Ⅱ.Conclusion Paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule have certain efficacy with slight toxic and adverse responses and favorable tolerance,becoming one of the optimal choices in treating elderly patients with advanced gastric carcinoma.
  • 王金万. 奥沙利铂治疗进展期胃癌国际临床试验研究进展 [J]. 癌症进展, 2008(6):537.
    金梅, 李建华. 老年胃癌患者内镜所见及病理特点 [J]. 中国临床保健杂志, 2008(3):252.
    秦叔逵, 龚新雷. 晚期胃癌化疗的现状和进展 [J]. 临床肿瘤学杂志, 2006(9):641.
    Fukushima M. Antitumor activity and function of S-1, a new oral tegafur-based formulation [J]. Gan To Kagaku Ryoho, 2006, (Suppl 1):19.
    Nagahama T, Ando M, Seki R. Preoperative chemotherapy for advanced gastric cancer [J]. Gan To Ka-gaku Ryoho, 2013, (12):2217.
    Katayanagi S, Nomura T, Sumi T. The efficacy of neoadjuvant chemotherapy with S-1/CDDP (SP)to the pa-tients with large type 3 and type 4 gastric cancer [J]. Gan To Kagaku Ryoho, 2013, (12):2214.
    Tsushima T, Hironaka S, Boku N. Safety and efficacy of s-1 monotherapy in elderly patients with avanced.gastric cancer [J]. GASTRIC CANCER, 2010(4):245.
    Pfister D, Heidenreich A, Porres D. Biomarker docetaxel-based chemotherapy [J]. Urologe Ausgabe A, 2013(9):1261.
    Gong J, Hu B, Zhang X. The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma [J]. Oncologist, 2014(2):173.
    Xu X, Wang L, Xu H Q. Clinical comparison between paclitaxel liposome(Lipusu)and paclitaxel for treatment of patients with metastatic gastric cancer [J]. Asian Pac J Can-cer Prev, 2013(4):2591.
    Yoneyama K, Konishi H, Yahata T. A phase Ⅱ study of paclitaxel and carboplatin with a biweekly schedule in pa-tients with epithelial ovarian cancer:Gynecologic Cancer Net-work trial [J]. Journal of Nippon Medical School, 2014(1):28.
    仲飞, 孙国平, 顾康生. 替吉奥胶囊联合奥沙利铂加与不加紫杉醇治疗晚期胃癌的比较研究 [J]. 临床肿瘤学杂志, 2013(6):530.
    Lee J L, Kang Y K, Kang H J. A randomised multi-centre phase Ⅱ trial of capecitabine vs.S-1 as first line treatment in elderly patients with metastatic or recarrent un-resectable gastric cancer [J]. British Journal of Cancer, 2008(4):584.
    Jung H C, Rha S Y, Im C K. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expres-sion for personalized therapy [J]. CANCER, 2011, (10):2050.

Catalog

    Article views (171) PDF downloads (0) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return